[CAS NO. 1025504-45-3] Valbenazine
PRODUCTS SPECIFICATIONS [1025504-45-3]
DESCRIPTION [1025504-45-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 418.57 |
| Molecular Formula | C24H38N2O4 |
| SMILES | O=C([C@@H](N)C(C)C)O[C@@H]1C[C@]2([H])C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC(C)C |
1 Publications Citing Use of MCE
Summary
Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 ( VMAT2 ) inhibitor with the K i of 110-190 nM [1] .
In Vitro
Valbenazine exhibits VMAT2 binding affinity in rat striatum and human platelets with Kis of 110 and 150 nM, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Valbenazine (10 mg/kg; orally) induces ptosis (primarily an adrenergic response) and increases plasma prolactin primarily a dopaminergic response in rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02879578 | Neurocrine Biosciences |
Tourette Syndrome
|
July 25, 2016 | Phase 2 |
| NCT01733121 | Neurocrine Biosciences |
Tardive Dyskinesia
|
December 2012 | Phase 2 |
| NCT03891862 | Neurocrine Biosciences |
Tardive Dyskinesia (TD)
|
March 18, 2019 | Phase 4 |
| NCT05110157 | Neurocrine Biosciences |
Schizophrenia
|
November 29, 2021 | Phase 3 |
| NCT01267188 | Neurocrine Biosciences |
Tardive Dyskinesia
|
January 2011 | Phase 2 |
| NCT02405091 | Neurocrine Biosciences |
Tardive Dyskinesia
|
March 2015 | Phase 3 |
| NCT02274558 | Neurocrine Biosciences |
Tardive Dyskinesia
|
October 2014 | Phase 3 |
| NCT05206513 | Neurocrine Biosciences |
Dyskinesia|Cerebral Palsy
|
April 15, 2022 | Phase 3 |
| NCT01688037 | Neurocrine Biosciences |
Tardive Dyskinesia
|
September 2012 | Phase 2 |
| NCT03530293 | Neurocrine Biosciences |
Tourette Syndrome
|
April 17, 2018 | Phase 2 |
| NCT02581865 | Neurocrine Biosciences |
Tourette Syndrome
|
November 2015 | Phase 2 |
| NCT01916993 | Neurocrine Biosciences |
Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
|
August 2013 | Phase 1 |
| NCT01910480 | Neurocrine Biosciences |
Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
|
July 2013 | Phase 1 |
| NCT03732534 | Neurocrine Biosciences |
Tourette Syndrome
|
October 17, 2018 | Phase 2 |
| NCT04102579 | Neurocrine Biosciences|Huntington Study Group |
Chorea, Huntington
|
November 13, 2019 | Phase 3 |
| NCT03698331 | Neurocrine Biosciences |
Tardive Dyskinesia (TD)
|
September 14, 2018 | Phase 4 |
| NCT01393600 | Neurocrine Biosciences |
Tardive Dyskinesia
|
August 2011 | Phase 2 |
| NCT02256475 | Neurocrine Biosciences |
Tourette Syndrome
|
September 2014 | Phase 1 |
| NCT03444038 | Neurocrine Biosciences |
Tourette Syndrome
|
February 8, 2018 | Phase 2 |
| NCT03325010 | Neurocrine Biosciences |
Tourette Syndrome
|
October 5, 2017 | Phase 2 |
| NCT02679079 | Neurocrine Biosciences |
Tourette Syndrome
|
March 23, 2016 | Phase 2 |
| NCT02736955 | Neurocrine Biosciences |
Tardive Dyskinesia
|
June 13, 2016 | Phase 3 |
| NCT04400331 | Neurocrine Biosciences|Huntington Study Group |
Chorea, Huntington
|
September 18, 2020 | Phase 3 |
| NCT05053321 | Yale University|Neurocrine Biosciences |
Tardive Dyskinesia
|
November 2022 | Phase 1 |
| NCT05207085 | Yale University|Neurocrine Biosciences |
Trichotillomania (Hair-Pulling Disorder)
|
November 15, 2022 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 119.45 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3891 mL | 11.9454 mL | 23.8909 mL |
| 5 mM | 0.4778 mL | 2.3891 mL | 4.7782 mL |
| 10 mM | 0.2389 mL | 1.1945 mL | 2.3891 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.97 mM); Clear solution
Synonyms